AU2013211850B8 - Methods for profiling and quantitating cell-free RNA - Google Patents

Methods for profiling and quantitating cell-free RNA Download PDF

Info

Publication number
AU2013211850B8
AU2013211850B8 AU2013211850A AU2013211850A AU2013211850B8 AU 2013211850 B8 AU2013211850 B8 AU 2013211850B8 AU 2013211850 A AU2013211850 A AU 2013211850A AU 2013211850 A AU2013211850 A AU 2013211850A AU 2013211850 B8 AU2013211850 B8 AU 2013211850B8
Authority
AU
Australia
Prior art keywords
tissue
cell
rna
free
biological sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013211850A
Other languages
English (en)
Other versions
AU2013211850A1 (en
AU2013211850B2 (en
AU2013211850A8 (en
Inventor
Hei-Mun Christina Fan
Lian Chye Winston Koh
Wenying Pan
Stephen R. Quake
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of AU2013211850A1 publication Critical patent/AU2013211850A1/en
Application granted granted Critical
Publication of AU2013211850B2 publication Critical patent/AU2013211850B2/en
Publication of AU2013211850B8 publication Critical patent/AU2013211850B8/en
Publication of AU2013211850A8 publication Critical patent/AU2013211850A8/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C12Q1/6874—Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F18/00—Pattern recognition
    • G06F18/20—Analysing
    • G06F18/21—Design or setup of recognition systems or techniques; Extraction of features in feature space; Blind source separation
    • G06F18/213—Feature extraction, e.g. by transforming the feature space; Summarisation; Mappings, e.g. subspace methods
    • G06F18/2135—Feature extraction, e.g. by transforming the feature space; Summarisation; Mappings, e.g. subspace methods based on approximation criteria, e.g. principal component analysis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Databases & Information Systems (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Public Health (AREA)
  • Bioethics (AREA)
  • Epidemiology (AREA)
  • Data Mining & Analysis (AREA)
  • Pathology (AREA)
  • Primary Health Care (AREA)
  • Artificial Intelligence (AREA)
  • Software Systems (AREA)
  • Evolutionary Computation (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Biomedical Technology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Chemical Kinetics & Catalysis (AREA)
AU2013211850A 2012-01-27 2013-01-28 Methods for profiling and quantitating cell-free RNA Active AU2013211850B8 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261591642P 2012-01-27 2012-01-27
US61/591,642 2012-01-27
PCT/US2013/023471 WO2013113012A2 (en) 2012-01-27 2013-01-28 Methods for profiling and quantitating cell-free rna

Publications (4)

Publication Number Publication Date
AU2013211850A1 AU2013211850A1 (en) 2014-09-18
AU2013211850B2 AU2013211850B2 (en) 2017-03-02
AU2013211850B8 true AU2013211850B8 (en) 2017-06-29
AU2013211850A8 AU2013211850A8 (en) 2017-06-29

Family

ID=48874081

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013211850A Active AU2013211850B8 (en) 2012-01-27 2013-01-28 Methods for profiling and quantitating cell-free RNA

Country Status (9)

Country Link
US (15) US20130252835A1 (enExample)
EP (2) EP3584327A1 (enExample)
JP (2) JP6320302B2 (enExample)
CN (2) CN104334742A (enExample)
AU (1) AU2013211850B8 (enExample)
CA (1) CA2863035C (enExample)
HK (1) HK1211624A1 (enExample)
SG (2) SG10201906331TA (enExample)
WO (1) WO2013113012A2 (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3216874A1 (en) 2008-09-05 2017-09-13 TOMA Biosciences, Inc. Methods for stratifying and annotating cancer drug treatment options
DK2496720T3 (da) 2009-11-06 2020-09-28 Univ Leland Stanford Junior Ikke-invasiv diagnose af transplantatafstødning i organ-transplanterede patienter
AU2011305445B2 (en) 2010-09-24 2017-03-16 The Board Of Trustees Of The Leland Stanford Junior University Direct capture, amplification and sequencing of target DNA using immobilized primers
EP3584327A1 (en) 2012-01-27 2019-12-25 The Board of Trustees of the Leland Stanford Junior University Methods for profiling and quantitating cell-free rna
US20160289762A1 (en) 2012-01-27 2016-10-06 The Board Of Trustees Of The Leland Stanford Junior University Methods for profiliing and quantitating cell-free rna
WO2015069900A1 (en) * 2013-11-06 2015-05-14 The Board Of Trustees Of The Leland Stanford Junior University Methods for profiliing and quantitating cell-free rna
US10689652B2 (en) 2013-10-02 2020-06-23 The Regents Of The University Of California Methods for immortalization of epithelial cells
WO2015069933A1 (en) * 2013-11-06 2015-05-14 The Board Of Trustees Of The Leland Stanford Junior University Circulating cell-free dna for diagnosis of transplant rejection
KR102205950B1 (ko) 2013-11-07 2021-01-22 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 인간 마이크로바이옴 및 그의 성분의 분석을 위한 무세포 핵산
CN107002122B (zh) 2014-07-25 2023-09-19 华盛顿大学 确定导致无细胞dna的产生的组织和/或细胞类型的方法以及使用其鉴定疾病或紊乱的方法
CA2965528A1 (en) 2014-11-14 2016-05-19 Liquid Genomics, Inc. Use of circulating cell-free rna for diagnosis and/or monitoring cancer
EP3298169B1 (en) 2015-05-18 2024-10-02 Karius, Inc. Compositions and methods for enriching populations of nucleic acids
WO2016205753A1 (en) * 2015-06-17 2016-12-22 The Translational Genomics Research Institute Systems and methods for obtaining biological molecules from a sample
US10692797B2 (en) * 2015-06-30 2020-06-23 Laird Technologies, Inc. Thermal interface materials with low secant modulus of elasticity and high thermal conductivity
WO2017062517A1 (en) * 2015-10-06 2017-04-13 The Regents Of The University Of California Non-coding rnas linked to immortality and associated methods and compositions
US10890592B2 (en) 2015-11-04 2021-01-12 Metabolon, Inc. Automated sample quality assessment
KR102326769B1 (ko) 2016-03-25 2021-11-17 카리우스, 인코포레이티드 합성 핵산 스파이크-인
CA3059370C (en) 2017-04-12 2022-05-10 Karius, Inc. Methods for concurrent analysis of dna and rna in mixed samples
KR20200003917A (ko) * 2017-05-10 2020-01-10 난토믹스, 엘엘씨 암의 검출, 예측, 및 모니터링을 위한 순환 rna(circulating rna for detection, prediction, and monitoring of cancer)
CN110869518A (zh) * 2017-05-16 2020-03-06 香港中文大学 整合式单细胞和游离血浆rna分析
SG11202003588QA (en) 2017-09-20 2020-05-28 Molecular Stethoscope Inc Methods and systems for detecting tissue conditions
EP3701043B1 (en) * 2017-10-23 2023-11-22 CZ Biohub SF, LLC A noninvasive molecular clock for fetal development predicts gestational age and preterm delivery
AU2018355575A1 (en) 2017-10-27 2020-05-21 Juno Diagnostics, Inc. Devices, systems and methods for ultra-low volume liquid biopsy
WO2019094363A2 (en) 2017-11-07 2019-05-16 Nanthealth Labs, Inc. Targeted cell free nucleic acid analysis
CA3082601A1 (en) 2018-03-16 2019-09-19 Karius, Inc. Sample series to differentiate target nucleic acids from contaminant nucleic acids
CA3095030A1 (en) 2018-03-30 2019-10-03 Juno Diagnostics, Inc. Deep learning-based methods, devices, and systems for prenatal testing
WO2020072829A2 (en) 2018-10-04 2020-04-09 Bluestar Genomics, Inc. Simultaneous, sequencing-based analysis of proteins, nucleosomes, and cell-free nucleic acids from a single biological sample
JP2022513399A (ja) * 2018-10-29 2022-02-07 モレキュラー ステソスコープ， インコーポレイテッド 無細胞メッセンジャーｒｎａを使用した骨髄の特徴付け
EP4700161A3 (en) 2018-11-21 2026-03-11 Karius, Inc. Direct-to-library methods, systems, and compositions
US11512349B2 (en) 2018-12-18 2022-11-29 Grail, Llc Methods for detecting disease using analysis of RNA
KR20260023068A (ko) * 2019-01-24 2026-02-20 일루미나, 인코포레이티드 장기 건강 및 질환을 모니터링하기 위한 방법 및 시스템
GB2615975B (en) 2019-02-14 2023-11-29 Mirvie Inc Methods and systems for determining a pregnancy-related state of a subject
AU2020253585A1 (en) * 2019-04-02 2021-11-18 Mission Bio, Inc. Methods, systems, and apparatus for nucleic acid detection
AU2020280104A1 (en) 2019-05-22 2022-01-20 Mission Bio, Inc. Method and apparatus for simultaneous targeted sequencing of DNA, RNA and protein
US11948684B2 (en) * 2019-06-20 2024-04-02 Latha Chakravarthy Diagnostic process for disease detection using gene expression based multi layer PCA classifier
CN110964800B (zh) * 2019-09-20 2021-10-22 北京航空航天大学 用于预测早产风险的cfRNA标志物
WO2021092224A1 (en) * 2019-11-05 2021-05-14 Cofactor Genomics, Inc. Methods and systems of processing complex data sets using artificial intelligence and deconvolution
MX2022005521A (es) * 2019-11-08 2022-06-08 Regeneron Pharma Desconvolucion precisa y consistente de informacion a partir de transcriptomas tisulares globales.
US20230008870A1 (en) * 2019-12-20 2023-01-12 University Of Utah Research Foundation Methods and compositions for monitoring and diagnosing healthy and disease states
US11211144B2 (en) 2020-02-18 2021-12-28 Tempus Labs, Inc. Methods and systems for refining copy number variation in a liquid biopsy assay
US11211147B2 (en) 2020-02-18 2021-12-28 Tempus Labs, Inc. Estimation of circulating tumor fraction using off-target reads of targeted-panel sequencing
US11475981B2 (en) 2020-02-18 2022-10-18 Tempus Labs, Inc. Methods and systems for dynamic variant thresholding in a liquid biopsy assay
MX2022011619A (es) * 2020-03-18 2023-02-09 Molecular Stethoscope Inc Sistemas y métodos para detectar un riesgo de enfermedad de alzheimer utilizando un ensayo de perfil de arnm libre de circulación.
MX2023001781A (es) * 2020-08-13 2023-04-26 Mirvie Inc Metodos y sistemas para determinar un estado relacionado con el embarazo de un sujeto.
WO2024182491A1 (en) * 2023-02-28 2024-09-06 Virginia Commonwealth University Polygenic risk estimator for cervical length change during pregnancy
WO2026101912A1 (en) * 2024-11-06 2026-05-15 Mirvie, Inc. Methods and systems for determining a pregnancy-related state of a subject

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004065629A1 (en) * 2003-01-17 2004-08-05 The Chinese University Of Hong Kong Circulating mrna as diagnostic markers for pregnancy-related disorders
WO2009025852A2 (en) * 2007-08-22 2009-02-26 Xenomics, Inc. Methods of using mirna for detection of in vivo cell death
WO2011156734A2 (en) * 2010-06-11 2011-12-15 Hitachi Chemical Co., Ltd. Method of characterizing vascular diseases

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5629147A (en) 1992-07-17 1997-05-13 Aprogenex, Inc. Enriching and identifying fetal cells in maternal blood for in situ hybridization
US5432054A (en) 1994-01-31 1995-07-11 Applied Imaging Method for separating rare cells from a population of cells
US20050123938A1 (en) * 1999-01-06 2005-06-09 Chondrogene Limited Method for the detection of osteoarthritis related gene transcripts in blood
WO2000040749A2 (en) * 1999-01-06 2000-07-13 Genenews Inc. Method for the detection of gene transcripts in blood and uses thereof
US20080009467A1 (en) 2000-05-01 2008-01-10 Accera, Inc. Combinations of medium chain triglycerides and therapeutic agents for the treatment and prevention of alzheimers disease and other diseases resulting from reduced neuronal metabolism
US6727066B2 (en) 2000-07-28 2004-04-27 Incyte Corporation Genes expressed in treated human C3A liver cell cultures
US6664056B2 (en) * 2000-10-17 2003-12-16 The Chinese University Of Hong Kong Non-invasive prenatal monitoring
US6977162B2 (en) * 2002-03-01 2005-12-20 Ravgen, Inc. Rapid analysis of variations in a genome
CA2484549A1 (en) 2002-05-10 2003-11-20 Phase-1 Molecular Toxicology, Inc. Liver inflammation predictive genes
AU2003272204A1 (en) 2002-07-12 2004-02-02 The Johns Hopkins University Neuronal and retinal gene expression patterns
US20040086511A1 (en) 2002-07-12 2004-05-06 The Johns Hopkins University Neuronal gene expression patterns
US20060003342A1 (en) * 2004-01-15 2006-01-05 Bianchi Diana W Fetal RNA in amniotic fluid to determine gene expression in the developing fetus
EP1877574A4 (en) * 2004-07-21 2009-05-06 Univ California SPEICHELTRANSKRIPTOMDIAGNOSE
US7713693B1 (en) * 2004-09-01 2010-05-11 University Of Louisiana At Monroe Human cancer cell specific gene transcript
CA2528531A1 (en) * 2005-01-06 2006-07-06 Mount Sinai Hospital Markers of pre-term labor
KR100686816B1 (ko) * 2005-07-22 2007-02-26 삼성에스디아이 주식회사 리튬 이차 전지
WO2007092473A2 (en) * 2006-02-02 2007-08-16 The Board Of Trustees Of The Leland Stanford Junior University Non-invasive fetal genetic screening by digital analysis
CA2659082A1 (en) 2006-06-07 2007-12-21 Tethys Bioscience, Inc. Markers associated with arteriovascular events and methods of use thereof
WO2008132752A2 (en) * 2007-05-01 2008-11-06 Tel Hashomer Medical Research Infrastructure And Services Ltd. Methods and kits for predicting cancer metastasis
WO2009009457A1 (en) 2007-07-06 2009-01-15 University Of Louisville Research Foundation, Inc. Alzheimer's disease-specific micro-rna microarray and related methods
WO2009073629A2 (en) * 2007-11-29 2009-06-11 Complete Genomics, Inc. Efficient shotgun sequencing methods
WO2009093254A2 (en) * 2008-01-27 2009-07-30 Rosetta Genomics Ltd. Methods and compositions for diagnosing complications of pregnancy
BRPI0906641A2 (pt) * 2008-01-30 2019-09-10 Novartis Ag enriquecimento de dois estágios de dna fetal livre de célula em plasma materno
WO2009134452A2 (en) * 2008-05-01 2009-11-05 Swedish Health Services Preterm delivery diagnostic assay
WO2009143576A1 (en) 2008-05-27 2009-12-03 Adelaide Research & Innovation Pty Ltd Polymorphisms associated with pregnancy complications
WO2009149026A2 (en) * 2008-06-01 2009-12-10 Tufts Medical Center, Inc. Genomic approaches to fetal treatment and diagnosis
US8252529B2 (en) * 2008-06-12 2012-08-28 The Invention Science Fund I, Llc Methods for collecting and detecting oligonucleotides
US7888030B2 (en) * 2008-08-21 2011-02-15 King's College London Biomarkers
US20110263441A1 (en) 2008-10-15 2011-10-27 Golub Todd R Compositions, kits, and methods for identification, assessment, prevention, and therapy of hepatic disorders
CN102271669A (zh) 2008-11-13 2011-12-07 基因改造有限责任公司 非大脑组织中β-淀粉样肽负载的改性
US8349563B2 (en) * 2008-11-18 2013-01-08 Life Technologies Corporation Sequence amplification with target primers
CN102741426B (zh) 2009-09-11 2015-03-25 香港中文大学 用于评估肝病变的方法
WO2011032053A1 (en) * 2009-09-11 2011-03-17 Nugen Technologies, Inc. Compositions and methods for whole transcriptome analysis
CA2807050C (en) * 2009-12-08 2019-06-18 Ozlem Equils Diagnostic biomarker to identify women at risk for preterm delivery
JP5755326B2 (ja) 2010-06-11 2015-07-29 日立化成株式会社 腎機能の特徴を決定する方法
CA2802305A1 (en) * 2010-07-08 2012-01-12 Pronota N.V. Biomarker for hypertensive disorders of pregnancy
SG10201505723UA (en) * 2010-07-23 2015-09-29 Harvard College Methods for detecting signatures of disease or conditions in bodily fluids
EP2729146B1 (en) 2011-07-08 2017-03-08 Helmholtz-Zentrum für Infektionsforschung GmbH Medicament for treatment of liver cancer
WO2013022953A2 (en) 2011-08-08 2013-02-14 Eugenia Wang Biomarker for alzheimer's disease and/or mild cognitively impairment, and use thereof
CA3069089A1 (en) 2011-09-22 2013-03-28 Lineage Biosciences, Inc. Compositions and methods for analyzing heterogeneous samples
KR102248900B1 (ko) 2011-09-30 2021-05-07 소마로직, 인크. 심혈관 위험 사건 예측 및 그것의 용도
WO2013066764A2 (en) 2011-10-31 2013-05-10 Merck Sharp & Dohme Corp. Alzheimer's disease signature markers and methods of use
US20160289762A1 (en) * 2012-01-27 2016-10-06 The Board Of Trustees Of The Leland Stanford Junior University Methods for profiliing and quantitating cell-free rna
EP3584327A1 (en) 2012-01-27 2019-12-25 The Board of Trustees of the Leland Stanford Junior University Methods for profiling and quantitating cell-free rna
WO2013135830A1 (en) 2012-03-14 2013-09-19 Ruprecht-Karls-Universität Heidelberg Epigenetic signatures as marker for cardiomyopathies and myocardial insufficiencies
WO2014142752A1 (en) * 2013-03-12 2014-09-18 Agency For Science, Technology And Research Pre-eclampsia biomarkers
WO2014150198A2 (en) 2013-03-15 2014-09-25 Somalogic, Inc. Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof
EP3303629A1 (en) 2015-06-05 2018-04-11 Regulus Therapeutics Inc. Non-alcoholic fatty liver disease biomarkers
MX2018003077A (es) 2015-09-14 2018-05-28 Genfit Metodos para diagnosticar y evaluar esteatohepatitis no alcoholica.
WO2017156310A1 (en) 2016-03-09 2017-09-14 Molecular Stethoscope, Inc. Methods and systems for detecting tissue conditions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004065629A1 (en) * 2003-01-17 2004-08-05 The Chinese University Of Hong Kong Circulating mrna as diagnostic markers for pregnancy-related disorders
WO2009025852A2 (en) * 2007-08-22 2009-02-26 Xenomics, Inc. Methods of using mirna for detection of in vivo cell death
WO2011156734A2 (en) * 2010-06-11 2011-12-15 Hitachi Chemical Co., Ltd. Method of characterizing vascular diseases

Also Published As

Publication number Publication date
WO2013113012A3 (en) 2014-11-06
US20210363584A1 (en) 2021-11-25
US20220290236A1 (en) 2022-09-15
US20190226029A1 (en) 2019-07-25
US20170145507A1 (en) 2017-05-25
CA2863035A1 (en) 2013-08-01
EP3584327A1 (en) 2019-12-25
US20160017420A1 (en) 2016-01-21
CN104334742A (zh) 2015-02-04
US10240200B2 (en) 2019-03-26
US20200370121A1 (en) 2020-11-26
US20180357379A1 (en) 2018-12-13
JP2017063799A (ja) 2017-04-06
US10155986B2 (en) 2018-12-18
US20170145509A1 (en) 2017-05-25
US20170145508A1 (en) 2017-05-25
EP2807277A4 (en) 2016-02-17
US10240204B2 (en) 2019-03-26
JP2015511122A (ja) 2015-04-16
EP2807277A2 (en) 2014-12-03
SG11201505515XA (en) 2015-09-29
US20200362416A1 (en) 2020-11-19
US20260055464A1 (en) 2026-02-26
JP6320302B2 (ja) 2018-05-09
US10287632B2 (en) 2019-05-14
AU2013211850A1 (en) 2014-09-18
AU2013211850B2 (en) 2017-03-02
US20220042098A1 (en) 2022-02-10
US20220010381A1 (en) 2022-01-13
US20130252835A1 (en) 2013-09-26
CA2863035C (en) 2023-08-29
CN108359711A (zh) 2018-08-03
SG10201906331TA (en) 2019-08-27
WO2013113012A2 (en) 2013-08-01
US12365947B2 (en) 2025-07-22
AU2013211850A8 (en) 2017-06-29
US20220213549A1 (en) 2022-07-07
HK1211624A1 (en) 2016-05-27

Similar Documents

Publication Publication Date Title
US12365947B2 (en) Methods for profiling and quantitating cell-free RNA
US20230250477A1 (en) Methods and systems for determining a pregnancy-related state of a subject
JP7334122B2 (ja) 妊娠高血圧腎症に特異的な循環ｒｎａシグネチャー
US12359256B2 (en) Circulating RNA signatures specific to preeclampsia
CN104981548A (zh) 用于阿尔茨海默氏病的诊断性miRNA标志物
WO2015069900A1 (en) Methods for profiliing and quantitating cell-free rna
CA3062985A1 (en) Integrative single-cell and cell-free plasma rna analysis
HK40062225A (en) Circulating rna signatures specific to preeclampsia
HK1238299A1 (en) Non-invasive prenatal diagnosis of fetal genetic condition using cellular dna and cell free dna
HK1238299B (en) Non-invasive prenatal diagnosis of fetal genetic condition using cellular dna and cell free dna

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ KOH, LIAN CHYE WINSTON; QUAKE, STEPHEN R.; FAN, HEIMUN CHRISTINA AND PAN, WENYING

TH Corrigenda

Free format text: IN VOL 29 , NO 28 , PAGE(S) 4203 UNDER THE HEADING AMENDMENTS - AMENDMENTS MADE UNDER THE NAME BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY, APPLICATION NO. 2013211850, UNDER INID (71) CORRECT THE APPLICANT NAME TO THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY

Free format text: IN VOL 28 , NO 37 , PAGE(S) 4978 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY, APPLICATION NO. 2013211850, UNDER INID (71) CORRECT THE APPLICANT NAME TO THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY

Free format text: IN VOL 31 , NO 8 , PAGE(S) 1257 UNDER THE HEADING APPLICATIONS ACCEPTED - NAME INDEX UNDER THE NAME BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY, APPLICATION NO. 2013211850, UNDER INID (71) CORRECT THE APPLICANT NAME TO THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired
NA Applications received for extensions of time, section 223

Free format text: AN APPLICATION TO EXTEND THE TIME FROM 28 JAN 2022 TO 28 JAN 2023 IN WHICH TO PAY A RENEWAL FEE HAS BEEN FILED

NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO PAY A RENEWAL FEE HAS BEEN EXTENDED TO 28 JAN 2023